# AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

> **NCT04058145** · PHASE2 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** AMD3100
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04058145
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-30
- **Primary completion:** 2019-10-11
- **Final completion:** 2019-10-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding Withdrawn
- **Last updated:** 2020-09-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058145, "AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04058145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*